MANGOCEUTICALS, INC.

For the period ended Mar 31, 2026. Filed May 19, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 19, 2026

MGRX$0.19-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

	For The Three Months	For The Three
	Ended	Ended
	March 31, 2026	March 31, 2025
	(Unaudited)	(Unaudited)
Revenues
Revenues	$67,864	$109,306
Cost of revenues	8,218	24,737
Cost of revenues - related party	30,645	22,505
Gross profit	29,001	62,064
Operating expenses
General and administrative expenses	1,054,122	1,542,444
Salary and benefits	346,860	349,783
Advertising and marketing	94,073	281,732
Investor relations	12,451	1,419,000
Stock based compensation	1,647,821	1,045,479
Total operating expenses	3,155,327	4,638,438
Loss from operations	(3,126,326)	(4,576,374)
Other (income) expense
Interest expense	-	(13,700)
Interest expense - amortization of intangible assets	276,815	276,815
Total other expense	276,815	263,115
Loss before income taxes	(3,403,141)	(4,839,489)
Income taxes	-	-
Net loss	(3,403,141)	(4,839,489)
Net income (loss) attributed to non-controlling interest	9	(98)
Net loss attributed to Mangoceuticals, Inc.	(3,403,150)	(4,839,391)
Basic and diluted loss per share
Basic and diluted loss per share	$(0.22)	$(1.12)
Weighted average number of shares outstanding
Basic and diluted	16,481,607	4,593,062
Basic and diluted loss per share calculation
Preferred stock dividend requirements	294,000	294,000
Net loss attributed to Mangoceuticals, Inc. common stockholders	$(3,697,150)	$(5,133,391)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.